Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow-Derived Mononuclear Cell Therapy vs Standard Treatment in Diabetic Chronic Limb-Threatening Ischemia
2024-519687-40-00Phase 3Authorised
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Jan 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of autologous bone marrow-derived mononuclear cell in chronic limb-threatening ischemia (CLTI), diabetic foot ulcer (DFU), diabetes mellitus type 1 (T1D) and 2 more (2 arms), sponsored by Institute for Clinical and Experimental Medicine. Primary endpoints: Improvement of ischemia parameters (tissue oxygenation) and Clinical effect. Planned start Jan 2025; status: authorised.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
chronic limb-threatening ischemia (CLTI)diabetic foot ulcer (DFU)diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)arteriosclerosis obliterans
Beyond the preview
Go deeper on 2024-519687-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519687-40-00.